GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Total Long-Term Liabilities

Halberd (Halberd) Total Long-Term Liabilities : $0.15 Mil (As of Jul. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Halberd's Total Long-Term Liabilities for the quarter that ended in Jul. 2023 was $0.15 Mil.


Halberd Total Long-Term Liabilities Historical Data

The historical data trend for Halberd's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Total Long-Term Liabilities Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Total Long-Term Liabilities
- 0.15 0.15

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Total Long-Term Liabilities - 0.15 0.15

Halberd Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.


Halberd Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Halberd's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Halberd (Halberd) Business Description

Industry
Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236